Osilodrostat

Isturisa (osilodrostat) is a small molecule pharmaceutical. Osilodrostat was first approved as Isturisa on 2020-01-09. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat cushing syndrome. The pharmaceutical is active against cytochrome P450 11B1, mitochondrial. In addition, it is known to target cytochrome P450 11B2, mitochondrial. Isturisa's patents are valid until 2035-10-12 (FDA).